Single Lower-Dose Medical Abortion Equally Effective

Article

Medical abortions using mifepristone 200 mg followed by vaginal misoprostol are 95% to 98% effective. A pilot study at Boston University suggests that mifeprestone 100 mg plus misoprostol at the same time is equally effective.

Medical abortions using mifepristone 200 mg followed by vaginal misoprostol are 95% to 98% effective. A pilot study at Boston University suggests that mifeprestone 100 mg plus misoprostol at the same time is equally effective.

Researchers led by Nathalie Kapp, MD, enrolled 40 women who wanted a medical abortion and had pregnancies up to 56 menstrual days by ultrasound exam. Women in the study were given half of a standard 200-mg mifepristone tablet orally and 800 mcg of misoprostol placed vaginally by a clinician. All of the women had follow-up exams 2 to 7 days later and a phone call after 3 weeks to evaluate symptoms and satisfaction. The 95% confidence level for matching the 95% success rate produced by higher-dose studies requires a confidence interval of 88% to 100% for 40 subjects.

One woman was lost to follow-up and the other 39 had visits as scheduled. Four women had uterine aspiration, one for nonviable pregnancy, two for incomplete abortion, and one for continuing pregnancy. The median time from medication to passage of pregnancy was 7 hours with a mean of 13.8 bleeding days. Nearly all of the women, 92%, strongly preferred taking both medications at the same time.

Kapp N, Borgatta L, Ellis SC, Vragovic O, Stubblefield P. Simultaneous low-dose mifepristone and vaginal misoprostol for medical abortion: How low can you go? Obstet Gynecol. 2005;105(4 suppl):57S.

Recent Videos
Expert discussions from the 2025 ACOG meeting | Image Credit: © stevengaertner - © stevengaertner - stock.adobe.com.
Trina Mansour, MD
Negative pressure wound therapy reduces c-section infections and costs | Image Credit: doctors.valleyhealth.com.
Amy Valent DO, MCR, highlights new tech for prenatal diabetes management | Image Credit: linkedin.com.
Lisa Bayer, MD, MPH
Megan Wasson, DO, FACOG
Megan Cohen, MD, MPH, outlines 2024 CDC contraception guidelines | Image Credit: linkedin.com.
Wasson and Colak
Johanna Finkle, MD, weight loss specialist, OB/GYN, The University of Kansas Health System.
Navigating hormone therapy in high-risk menopause cases | Image Credit: © dhaj7-cepo.com.
© 2025 MJH Life Sciences

All rights reserved.